Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Clinical Kidney Journal|September 10, 2025
The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and managementFrancesc Moncho, Salvador Benlloch, Jose Luis GórrizNefrologia|April 2, 2024
Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to actionSalvador Benlloch, Francesc Moncho, Jose Luis GórrizNefrologia|September 13, 2025
Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitusAlberto Ortiz, Ana Cebrián, Alfonso Soto, et al.Primary Care Diabetes|August 12, 2019
Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary careJose Luis Górriz, Francesc Xavier Cos Claramunt, Natalia Duque, et al.Kidney International. Supplement|May 2, 2002
An update on the referral pattern of patients with end-stage renal diseaseNorbert Lameire, Jean-Pierre Wauters, Jose Luis Górriz Teruel, et al.Nefrologia|October 9, 2023
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney diseaseJose Luis Górriz, José Ramón González-Juanatey, Lorenzo Facila, et al.Annals of Medicine|January 31, 2023
Cardiorenal benefits of finerenone: protecting kidney and heartJosé R González-Juanatey, Jose Luis Górriz, Alberto Ortiz, et al.Nefrologia|September 26, 2022
Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overviewRafael de la Espriella, Enrique Santas, Isabel Zegri Reiriz, et al.Journal of Clinical Medicine|October 30, 2015
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Jose Luis Górriz, Javier Nieto, Juan F Navarro-González, et al.ESC Heart Failure|December 14, 2019
Refractory congestive heart failure: when the solution is outside the heartVicente Pernias, Miguel González, Gema Miñana, et al.Pageof 4